Nyxoah SA filings document the company's foreign-private-issuer reporting for its medical-technology business and the Genio system for obstructive sleep apnea. Form 6-K reports furnish quarterly and annual operating results, press releases, manufacturing-capacity updates, clinical and regulatory disclosures, and information incorporated by reference into registration statements on Form S-8 and Form F-3.
The filing record also covers capital-structure and governance matters, including ordinary-share offerings, underwriting agreements, shareholder voting matters, transparency-related ownership information, material-event reports, and exhibits that describe financing terms and public-company obligations.
Cochlear Investments Pty Ltd and Cochlear Limited have updated their ownership disclosure for Nyxoah SA. Cochlear Investments directly holds 5,847,283 Ordinary Shares, which represents 5.91% of Nyxoah’s outstanding Ordinary Shares, based on 98,894,961 shares outstanding as stated in a recent prospectus supplement.
Cochlear Limited, as the parent of Cochlear Investments, may be deemed to indirectly beneficially own the same 5,847,283 shares, with shared voting and dispositive power reported and no sole voting or dispositive power. The filing states that the reporting persons have not conducted any transactions in Nyxoah shares during the past 60 days and do not have rights to acquire additional Ordinary Shares.
Nyxoah entered an underwriting agreement for an underwritten public offering of 55,232,558 ordinary shares at $1.72 (€1.48) per share, with underwriters holding a 30-day option to buy up to 8,284,883 additional shares at the same price, less fees. The deal is expected to generate gross proceeds of about $95 million and net proceeds of approximately $88.5 million (€76.3 million), assuming no exercise of the option, and is expected to close around June 9, 2026 subject to customary conditions. All shares are issued by Nyxoah under its effective Form F-3 shelf, and the company plans to use proceeds to fund U.S. commercialization, Genio system R&D and upgrades, international rollout, clinical research, and general corporate purposes including potential debt repayment and acquisitions. Nyxoah also intends to draw €13.8 million from the second tranche of its European Investment Bank loan in Q2 2026.
Nyxoah is offering 55,232,558 ordinary shares pursuant to a prospectus supplement dated June 5, 2026. The public offering price is €1.48 per share (equivalent to $1.72 per share), with estimated net proceeds of $88.5 million (€76.3 million), and an underwriter option to purchase an additional 8,284,883 ordinary shares to cover over-allotments for 30 days.
The offering would increase shares outstanding from 43,662,403 as of March 31, 2026 to 98,894,961 ordinary shares immediately after the offering (or 107,179,844 if the underwriters exercise the full option). Net proceeds are allocated principally to U.S. commercialization, R&D for Genio system upgrades and manufacturability, international commercialization, clinical data and general corporate purposes.
Nyxoah reports a planned Chief Executive Officer transition as it searches for a U.S.-based leader while current CEO Olivier Taelman continues to run day-to-day operations through the handover. The company highlights its funding history, noting €332.5 million of equity raised since inception and cash, cash equivalents and financial assets of €25.9 million with an accumulated deficit of €321.7 million as of March 31, 2026. Based on its operating plan and existing resources, including a loan facility tranche, Nyxoah expects its cash runway to extend into the third quarter of 2026.
The company describes available financing tools, including a $200.0 million Form F-3 shelf registration that covers an ATM program of up to $50.0 million, of which $32.8 million had been sold by December 31, 2024. Operationally, Nyxoah is expanding U.S. commercialization of its Genio system, with over 1,000 patients treated in Europe and 82% achieving an AHI below 15 at 12 months in the DREAM trial. In the United States, it now has about 60 commercial staff, 207 trained surgeons, 91 active accounts after a 60% quarter-over-quarter increase, and 241 patients submitted under prior authorizations, while achieving a 25% market share in Germany within 24 months of launch and 53% implant growth in 2025 versus 2024.
Nyxoah also outlines ongoing patent disputes with Inspire Medical Systems in the United States and Europe, including consolidated U.S. litigation and Unified Patent Court actions in Germany, and notes that its inter partes review petitions against certain Inspire patents were denied institution. The company emphasizes that outcomes of these legal proceedings are uncertain and could involve costs and other adverse impacts.
Nyxoah SA is offering ordinary shares pursuant to this preliminary prospectus supplement, with underwriters granted a 30-day option to purchase additional shares to cover over-allotments. The company reported 43,662,403 ordinary shares outstanding as of March 31, 2026 and stated cash, cash equivalents and financial assets of €25.9 million as of March 31, 2026. The prospectus supplement describes use of proceeds to expand U.S. commercialization, fund R&D and manufacturing initiatives, advance international commercialization and for general corporate purposes. Recent developments disclosed a leadership transition process to appoint a U.S.-based CEO and an expected draw of €13.8 million from the second tranche of a European Investment Bank loan in Q2 2026. The filings also describe ongoing patent litigation and inter partes review proceedings with Inspire Medical Systems and the consolidation of related Delaware actions by the court.
Nyxoah SA reported strong revenue growth and detailed governance items in its latest update. First quarter 2026 revenue rose to €6.4 million, up from €1.1 million a year earlier, driven mainly by U.S. Genio system commercialization and continued international sales. Gross margin was 57% on cost of goods sold of €2.7 million. Operating loss remained high at €20.5 million, with a net loss of €15.9 million, reflecting heavy R&D and U.S. commercial spending. Cash, cash equivalents and financial assets totaled €25.9 million as of March 31, 2026, and management highlights significant doubt about the company’s ability to continue as a going concern without additional funding.
The company will hold its annual shareholders’ meeting on June 10, 2026, immediately followed by an extraordinary meeting to renew authorized capital, ratify change‑of‑control protection in its convertible bonds and reappoint or appoint several directors, including one new independent director.
Nyxoah SA reported 2025 revenue of €10.02 million, compared with €4.521 million in 2024, as Genio sales expanded, including U.S. sales following FDA approval on August 8, 2025. Its operating loss was €83.485 million and net loss was €90.085 million, versus €58.809 million and €59.236 million, respectively, in 2024. Net cash used in operating activities was €68.979 million, compared with €49.226 million in 2024.
At December 31, 2025, cash and cash equivalents were €30.0 million and financial assets were €18.0 million. Nyxoah disclosed substantial doubt about its ability to continue as a going concern for at least 12 months from the annual report date. Its cash runway is expected to extend into the first quarter of 2027, taking into account full convertible bond financing and a second European Investment Bank loan tranche, which depends on a revenue milestone expected in the first half of 2026. The company said it may not be able to fund operations for at least 12 months from the annual report date.
Nyxoah SA reported strong revenue growth in 2025 as it began full commercial activity in the U.S. for its Genio system. Net revenue rose to €10.0 million from €4.5 million in 2024, driven mainly by the U.S. launch after FDA approval.
Despite higher sales, the company remained deeply loss-making, with a full-year operating loss of €83.5 million and a net loss of €90.1 million, reflecting heavy spending on research, clinical programs and U.S. commercial build-out. Cash, cash equivalents and financial assets totaled €48.0 million at December 31, 2025.
Nyxoah also updated its capital structure, disclosing 43,662,403 voting shares outstanding and 225 convertible bonds, and reported transparency notifications showing Robert Taub and related entities holding 9.99% of voting rights and BNP Paribas Asset Management Europe SAS holding 3.00%.
Nyxoah SA furnished a report highlighting preliminary, unaudited financial and operating results for the fourth quarter and full year 2025 and providing revenue guidance commentary for the first quarter of 2026. The Company’s first full quarter of U.S. commercialization after FDA approval generated what management describes as strong momentum, with early U.S. patients seeing positive outcomes, a waiting list for additional surgeon training, and patients already scheduled for implants.
Management stated that global revenue exceeded €10 million, supported by the U.S. launch and continued international expansion. Nyxoah also noted it will present at the 44th Annual J.P. Morgan Healthcare Conference, offering investors an opportunity to hear more about its commercialization progress and outlook.